Indication
Symbicort Turbohaler 200/6 as reliever therapy for adults and adolescents ≥12 years with mild asthma
Medicine details
- Medicine name:
- budesonide/formoterol (Symbicort)
- SMC ID:
- SMC|2622
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Publication due date:
- 26 October 2023
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC